Topic: How To Invest

Wall Street Stock Forecaster Hotline – Friday, October 13, 2017

Article Excerpt

PFIZER INC. $36.34, New York symbol PFE, is one of the world’s leading prescription drugmakers. The company announced this week that it is conducting a strategic review of its consumer products business. That operation makes a variety of over-the-counter treatments, including Advil (pain relief), Centrum (vitamins) and Robitussin (cough syrup). In 2016, revenue from its consumer products business totalled $3.4 billion. That’s equal to 6% of Pfizer’s total revenue of $52.8 billion. Depending on the results of its review, Pfizer may opt to sell all or part of the consumer business or spin it off as a separate firm. It expects to complete the process in 2018. Whatever the outcome, the review helps draw investor attention to the company’s value. OUR RECOMMENDATION: Pfizer is a buy. Pfizer recent coverage Hotline for August 4, 2017 August 2017 issue WAL-MART STORES INC., $86.62, New York symbol WMT, is the world’s largest retailer, with 11,652 locations in 28 countries. The stock jumped 10% this week after Wal-Mart…